The 1st patient has been dosed in the P-I/II trial evaluating AU-007 at 4 locations in Australia & 1 site in Huntersville, North Carolina
The P-I trial consists of 3 dose escalation arms of AU-007 as monotx. or in combination with a single loading dose of recombinant human IL-2 (aldesleukin) or with AU-007 & aldesleukin administered q2w. To define the safety & initial efficacy of AU-007, the P-II portion of the trial will assess the dosing regimen selected from dose escalation for expansion in specified tumor types
The early clinical data & strong preclinical data showed that AU-007 was found to be safe & well tolerated. AU-007 is a mAb that was computationally created by Biolojic Design to harness the power of IL-2 & kill solid tumors
Ref: Businesswire | Image: Aulos Bioscience
Related News:- Teon Therapeutics Entered into a Clinical Trial Collaboration with Merck to Evaluate TT-816 + Keytruda (pembrolizumab) for Solid Tumors
